Gyre Therapeutics (GYRE) Non-Current Deferred Tax Liability (2023 - 2025)

Gyre Therapeutics (GYRE) has 3 years of Non-Current Deferred Tax Liability data on file, last reported at $9.6 million in Q4 2025.

• Non-Current Deferred Tax Liability for Q4 2025 came in at $9.6 million, up 15.66% year-over-year; the trailing twelve-month figure through Dec 2025 was $9.6 million (up 15.66% YoY), and the FY2025 annual result was $9.6 million, up 15.66% from the prior year.
• Non-Current Deferred Tax Liability rose to $9.6 million in Q4 2025 per GYRE's latest filing, from $8.3 million in the prior quarter.
• Over five years, Non-Current Deferred Tax Liability peaked at $9.6 million in Q4 2025 and troughed at $2.5 million in Q4 2023.
• A 3-year average of $6.8 million and a median of $8.3 million in 2024 frame the typical range for Non-Current Deferred Tax Liability.
• The sharpest annual moves came in 2024 and 2025: Non-Current Deferred Tax Liability surged 232.0% in 2024, then climbed 15.66% in 2025.
• A 3-year view of Non-Current Deferred Tax Liability shows it stood at $2.5 million in 2023, then surged by 232.0% to $8.3 million in 2024, then increased by 15.66% to $9.6 million in 2025.
• Business Quant data shows GYRE's Non-Current Deferred Tax Liability at $9.6 million in Q4 2025, $8.3 million in Q4 2024, and $2.5 million in Q4 2023.